Takahide HosokawaChikako NakayamaKazu NorisugiShōichi NakamuraYasuki SaekiTakehiko SatōNorikichi YatsunamiEiichi ChishimaToshiaki HaradaKeiji YoshidaYūichi WadaHarue KuniedaСаката, МитиоJintarō ŌseYukio AndōMitsunori TeradaTakeo OgawaHiroshi KomatsuOsamu YamaguchiYasuhide IwasakiKeiichi KudōSōta HiragaYorio HinumaKazuaki KinoshitaYasufumi KijimaFumio KidaMasujiro HondaKyōichi SugitaniMasao MatsuokaMichisuke MatsumotoMasaaki MatsumotoIchirō MatsudaКуримото, Томэи桂英昭Masato MoriJirō NudeshimaTetsuo SakuraiSakurai FusakiTadao TakeuchiMitsuho Ikeda
P108
Impaired Peripheral Endothelial Function and In-stent RestenosisAn Investigational Study to Evaluate Experimental Medication BMS-986165 Compared to Placebo and a Currently Available Treatment in Participants With Moderate to Severe Plaque PsoriasisA Trial of Telmisartan Prevention of Cardiovascular DiseaseA Japanese Phase 1/2 Study to Assess the Efficacy, Safety and Pharmacokinetics of Romidepsin in Patients With Peripheral T-cell Lymphoma (PTCL)Safety and Efficacy of Tafamidis in Patients With Transthyretin CardiomyopathyA Study Of PF-05280014 [Trastuzumab-Pfizer] Or Herceptin® [Trastuzumab-EU] Plus Paclitaxel In HER2 Positive First Line Metastatic Breast Cancer Treatment (REFLECTIONS B327-02)A Study of Atezolizumab in Patients With Unresectable, Locally Advanced or Metastatic Non-small Cell Lung CancerJapanese Primary Prevention of Atherosclerosis With Aspirin for Diabetes (JPAD) TrialPrognostic Value of Endothelial Dysfunction and Coronary ComplexityPemafibrate to Reduce Cardiovascular OutcoMes by Reducing Triglycerides IN patiENts With diabeTes (PROMINENT)Phase 3 Study of BGB-A317 Versus Sorafenib in Patients With Unresectable HCCEfficacy and Safety of WTX101 Administered for 48 Weeks Versus Standard of Care in Wilson Disease SubjectsMesenteric Approach vs. Conventional Approach for Pancreatic CancerStudy to Assess Safety and Efficacy of Atezolizumab (MPDL3280A) Compared to Best Supportive Care Following Chemotherapy in Patients With Lung Cancer [IMpower010]A Study of Tislelizumab (BGB-A317) in Combination With Chemotherapy as First Line Treatment in Patients With Advanced Esophageal Squamous Cell CarcinomaA Study of Mirikizumab (LY3074828) in Participants With Crohn's DiseaseLong-Term Outcomes of Ataluren in Duchenne Muscular DystrophyStudy of Atezolizumab as Monotherapy and in Combination With Platinum-Based Chemotherapy in Participants With Untreated Locally Advanced or Metastatic Urothelial CarcinomaA Study of Atezolizumab in Combination With Bevacizumab Versus Sunitinib in Participants With Untreated Advanced Renal Cell Carcinoma (RCC)Avelumab in First-Line Maintenance Gastric Cancer (JAVELIN Gastric 100)A Study of Atezolizumab in Combination With Nab-Paclitaxel Compared With Placebo With Nab-Paclitaxel for Participants With Previously Untreated Metastatic Triple-Negative Breast Cancer (IMpassion130)Ipatasertib Plus Abiraterone Plus Prednisone/Prednisolone, Relative to Placebo Plus Abiraterone Plus Prednisone/Prednisolone in Adult Male Patients With Metastatic Castrate-Resistant Prostate CancerA Study of the Efficacy and Safety of Tocilizumab in Participants With Systemic Sclerosis (SSc)Clinical Study to Compare the Efficacy and Safety of Macitentan and Tadalafil Monotherapies With the Corresponding Fixed-dose Combination Therapy in Subjects With Pulmonary Arterial Hypertension (PAH)
P6153
Reiko SakaguchiAkiyoshi FumieMotoko KohamaMaako NakagamiYoshitaka NakayamaMasaomi MarukiKichio InoueAkira MitsuokaToshinobu KojōСаката, МитиоKeisetsu ŌtsukaHōei ŌhamaKatsurō ŌnoKeisuke MoriYukio AndōFukiko YasunagaМиядзаки, ТакафумиYūko OnoOkitomo YamaguchiAsami OkadaKeiichirō OkabeAkane IwaiKōichi IwashiroХиракава, АяматиYūta GotōKeiko SaitōMasaharu UdōTakashi KijimaMika MurakamiTakayuki HigashiMasao MatsuokaKunihiro MatsukiJun KuwaharaYukinori KuwanoКадзикава, ЁсихироMasato MoriKōichirō MoritaTsuneyuki MōriMichiko NagahataTetsuya Egoshi
P69
Q10377889-4A207B3C-8808-4634-8231-6F589C02DBEDQ11364195-2B2E2FE9-CE00-4216-AFA1-8482B8E17B49Q11369825-5C9A5C54-4839-47DC-9BFF-9C17F5789AF9Q11378548-7B415793-AA77-4DB9-8BFE-839ADACDC8F0Q11382854-A4957511-7C52-4AAF-B50C-26746B4AF17BQ11384185-E4137F5C-6BAA-4131-AE12-5F9E4DBE84D1Q11391508-84F4CEDE-848E-4231-97C1-7E5CF7868011Q11405466-2FC98A3B-AE88-4BD7-8EAC-1B893DA3D7E7Q11409850-8C362B06-BF46-46B2-A05A-1F9A7B2B4A6DQ11413917-A823BF06-D689-4D24-A5A1-0BE985A204E1Q11417932-7CF3859E-AD00-4AE0-B72E-E27E93432C9EQ11420991-76C6CBD2-5A88-491B-9EDB-D1771C94894DQ11425540-718A6D9E-E0F2-485B-B78C-8F554B52DB93Q11437695-6DA5CDEA-4841-4CC7-9073-BC28A1A250A3Q11450843-BB0AA13F-874D-4E1E-A66C-D8AC7ECC0732Q11457971-1C8EE5BE-7457-4600-B590-398C71F564DCQ11460375-CA91F6BD-BF21-4AF5-9919-8AAF942FCE92Q11461243-F7A65AB3-5CA9-4F5B-B0D4-E063A0375745Q11466652-D34ADA31-E643-4BCB-BB65-81FECDC26422Q11474519-76655C6B-C180-4848-9E5B-FC07A1A8B431Q11479583-F59C4A1B-2E09-4F7E-A488-AF4E28022DE5Q11483562-7EEC57D8-EB18-4DD1-8F59-F4AF4249182EQ11509625-FE785783-5543-482D-9B0F-BFA6A0E31047Q11518009-1CE7F081-896E-4799-8B5C-4EA40B1CEAE7Q11518337-A9F11DF6-B881-4FF8-B81A-0704743A205AQ11519298-C0E2BE19-2807-4A98-8A11-114884B8B2B4Q11520577-7B89A577-0237-49D7-9A1B-909FDCA89566Q11522345-5C092FE7-26F3-474F-8904-273D72BA2A0EQ11530078-DB402ABA-FDE7-4739-87B8-409741AA8EB5Q11531327-40F602E9-7286-4E93-9E87-FD3C61C2ABD7Q11531353-C60AA8C8-6AE9-40F1-8150-FEE53E048813Q11531966-1F0DBEB7-1A2E-47D4-A0DC-AC8400A0AD64Q11535968-28D68902-05B2-4044-90F0-12FEB1A0F59AQ11536893-C1CD1B16-1FB5-4F61-859F-E5E94939DE72Q11539908-E9C13FC5-6F06-4278-A485-2635F0778135Q11544560-4354AFD1-1F86-4876-ACF8-068EE222C13EQ11544760-E9FEEF3B-7239-42ED-8136-E6D27BB577F7Q11544773-49A2C439-6A27-4D5C-B6AC-13D9E4CFAA42Q11545821-38BD8246-2B19-4A51-9F42-6CDFC327DD5FQ11551725-5D35ABE9-50A1-46CB-ACBA-845B2DC14D8C
P108
Q61894283-6EAE62D2-CF22-4736-A6B3-5537A60E89CDQ61902320-F87E96D7-78B7-44B6-A7EC-80D49809DAD3Q61938210-3F6F2E38-72DC-4C33-B69B-CA84F84B72AEQ61966088-8AFC2914-1043-4736-BF7B-E60F3478DEDDQ61969733-1F58023D-E28D-4A55-9A8E-E76B71E6DA53Q61970155-E9661DFC-27A1-42E3-9BC0-E80B73174B06Q62025833-6D1AAA99-64B5-4D24-B709-917988BC7F8EQ62105220-B60900B5-50F5-4E75-9F66-585B1982928CQ63063117-0DC64B5D-FC8E-4B12-82CC-B227111D3F25Q63229004-881DC578-BCD8-4C7F-8EFF-1C2F168A67CEQ63402028-0EF153A0-5A81-45F3-9FE7-6A4EE5F34556Q63405264-13FC232C-C84E-4096-B121-B07CF6C8BC16Q63535143-D962A727-FBF9-4F8F-BD55-D8DA954B6596Q63571350-091887F3-9BBA-4F79-8E3F-3223C26599A1Q63572863-0D994B39-67AF-4F6C-B14E-4B74C4798952Q63572882-7F47739C-757C-4A0F-BCF0-950A74660B4AQ63573262-FF3CA932-9654-4616-B0CB-D2887EE5C381Q63577765-B7A805BC-EF44-4AC8-988D-5286BBEC7E2EQ64140172-8E29CB89-E432-48AD-87D8-2650D1135969Q64151487-A9E77754-5E6C-480F-8E60-3B0D3B6255F9Q64151685-C3133A32-65DC-4807-9566-7AC16775BBD1Q64172768-4F4F8FF9-AB8C-41FC-A606-57FAD8EF9A3BQ64172978-251525B2-3B17-4F4E-AF66-94144F56CF44Q64184905-F003110A-F5CB-437B-AE6E-60508F8BFFE5
P6153
description
Universität in Japan
@de
higher education institution in Kumamoto Prefecture, Japan
@en
japonská univerzita
@cs
universitas di Jepang
@id
universiteit in Japan
@nl
אוניברסיטה ביפן
@he
جامعة في كوماموتو، اليابان
@ar
熊本県の国立大学
@ja
name
Kumamoto University
@en
Kumamotská univerzita
@cs
Ollscoil Kumamoto
@ga
Prifysgol Kumamoto
@cy
Unibersidad ng Kumamoto
@tl
Universidad de Kumamoto
@es
Universidá de Kumamoto
@ast
Universität Kumamoto
@de
université de Kumamoto
@fr
אוניברסיטת קוממטו
@he
type
label
Kumamoto University
@en
Kumamotská univerzita
@cs
Ollscoil Kumamoto
@ga
Prifysgol Kumamoto
@cy
Unibersidad ng Kumamoto
@tl
Universidad de Kumamoto
@es
Universidá de Kumamoto
@ast
Universität Kumamoto
@de
université de Kumamoto
@fr
אוניברסיטת קוממטו
@he
altLabel
Kumamoto Daigaku
@de
Kumamoto Daigaku
@en
Kumamoto daigaku
@cs
Kumamoto-Universität
@de
くまもとだいがく
@ja
熊大
@ja
熊本大
@ja
熊本大学教育学部附属教育実践総合センター
@ja
熊本大学附属学校
@ja
prefLabel
Kumamoto University
@en
Kumamotská univerzita
@cs
Ollscoil Kumamoto
@ga
Prifysgol Kumamoto
@cy
Unibersidad ng Kumamoto
@tl
Universidad de Kumamoto
@es
Universidá de Kumamoto
@ast
Universität Kumamoto
@de
université de Kumamoto
@fr
אוניברסיטת קוממטו
@he